Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial-Reference-Cited by-同舟云学术

Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial

Published:2013-03-10 Issue:7 Volume:14 Page:437-444
ISSN:1464-2662
Container-title:HIV Medicine
language:en
Short-container-title:HIV Med

Author:

Sension M¹,Cahn P²,Domingo P³,Hodder S⁴,Opsomer M⁵,Lathouwers E⁵,Van de Casteele T⁵,Tomaka F⁶

Affiliation:

1. Comprehensive Care Center; Fort Lauderdale; FL; USA

2. Huésped Foundation; Buenos Aires; Argentina

3. Autonomous University of Barcelona; Barcelona; Spain

4. University of Medicine and Dentistry of New Jersey; Newark; NJ; USA

5. Janssen Infectious Diseases BVBA; Beerse; Belgium

6. Janssen Research & Development; LLC; Titusville; NJ; USA

Publisher

Wiley

Subject

Pharmacology (medical),Infectious Diseases,Health Policy

Reference26 articles.

1. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial;Madruga;Lancet,2007

2. Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96;Arastéh;Antivir Ther,2009

3. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients;Haubrich;AIDS,2007

4. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1;Katlama;AIDS,2007

5. Once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis;Mills;AIDS,2009

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bictegravir/emtricitabine/tenofovir alafenamide in patients with genotypic NRTI resistance;HIV Medicine;2022-08-16

2. Optimizing switching strategies to simplify antiretroviral therapy: the future of second-line from a public health perspective;AIDS;2021-12-15

3. Population Pharmacokinetic Analysis of Darunavir and Tenofovir Alafenamide in HIV-1-Infected Patients on the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen (AMBER and EMERALD Studies);The AAPS Journal;2021-06-07

4. Clinical outcomes of once-daily darunavir in treatment-experienced patients with darunavir resistance-associated mutations through 48 weeks of treatment;International Journal of STD & AIDS;2020-07-23

5. Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV‐1 resistance mutation;HIV Medicine;2020-01-11